These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 25983023

  • 1. Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.
    McCune JS, Mager DE, Bemer MJ, Sandmaier BM, Storer BE, Heimfeld S.
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):85-96. PubMed ID: 25983023
    [Abstract] [Full Text] [Related]

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 3. A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
    McCune JS, Woodahl EL, Furlong T, Storer B, Wang J, Heimfeld S, Deeg HJ, O'Donnell PV.
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):263-72. PubMed ID: 21909959
    [Abstract] [Full Text] [Related]

  • 4. A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.
    Woodahl EL, Wang J, Heimfeld S, Sandmaier BM, O'Donnell PV, Phillips B, Risler L, Blough DK, McCune JS.
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):391-401. PubMed ID: 18398611
    [Abstract] [Full Text] [Related]

  • 5. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.
    Bemer MJ, Sorror M, Sandmaier BM, O'Donnell PV, McCune JS.
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):607-18. PubMed ID: 23907443
    [Abstract] [Full Text] [Related]

  • 6. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 7. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 8. Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.
    Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T, Daulne C, de Bock M, Fillet M, Ory A, Willems E, Gothot A, Humblet-Baron S, Baron F.
    Clin Cancer Res; 2015 Jul 15; 21(14):3131-9. PubMed ID: 25779951
    [Abstract] [Full Text] [Related]

  • 9. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
    Baron F, Zachée P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, Willems E, Emonds MP, De Becker A, Beguin Y.
    J Hematol Oncol; 2015 Feb 06; 8():4. PubMed ID: 25652604
    [Abstract] [Full Text] [Related]

  • 10. Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.
    Sanghavi K, Wiseman A, Kirstein MN, Cao Q, Brundage R, Jensen K, Rogosheske J, Kurtzweil A, Long-Boyle J, Wagner J, Warlick ED, Brunstein CG, Weisdorf DJ, Jacobson PA.
    Transl Res; 2016 Sep 06; 175():103-115.e4. PubMed ID: 27094990
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.
    Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J.
    Biol Blood Marrow Transplant; 2017 Oct 06; 23(10):1701-1713. PubMed ID: 28684371
    [Abstract] [Full Text] [Related]

  • 12. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R, Fürst S, El-Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo R, Oudin C, Mohty B, Bouabdallah R, Chabannon C, Stoppa AM, Charbonnier A, Broussais-Guillaumot F, Calmels B, Lemarie C, Rey J, Vey N, Blaise D.
    Biol Blood Marrow Transplant; 2014 Mar 06; 20(3):370-4. PubMed ID: 24315846
    [Abstract] [Full Text] [Related]

  • 13. Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy.
    Takahashi T, Scheibner A, Cao Q, Pearson R, Sanghavi K, Weisdorf DJ, Brunstein CG, Rogosheske J, Bachanova V, Warlick ED, Wiseman A, Jacobson PA.
    Transplant Cell Ther; 2021 Sep 06; 27(9):773.e1-773.e8. PubMed ID: 34044184
    [Abstract] [Full Text] [Related]

  • 14. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.
    Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger G, Schleyer E, Bornhauser M.
    Bone Marrow Transplant; 2007 Feb 06; 39(4):201-6. PubMed ID: 17211431
    [Abstract] [Full Text] [Related]

  • 15. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.
    Bone Marrow Transplant; 2007 Feb 06; 39(4):193-9. PubMed ID: 17220905
    [Abstract] [Full Text] [Related]

  • 16. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT.
    Biol Blood Marrow Transplant; 2006 Aug 06; 12(8):868-75. PubMed ID: 16864057
    [Abstract] [Full Text] [Related]

  • 17. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
    Baron F, Maris MB, Storer BE, Sandmaier BM, Panse JP, Chauncey TR, Sorror M, Little MT, Maloney DG, Storb R, Heimfeld S.
    Leukemia; 2005 May 06; 19(5):822-8. PubMed ID: 15772701
    [Abstract] [Full Text] [Related]

  • 18. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
    Long-Boyle JR, Green KG, Brunstein CG, Cao Q, Rogosheske J, Weisdorf DJ, Miller JS, Wagner JE, McGlave PB, Jacobson PA.
    Bone Marrow Transplant; 2011 Jan 06; 46(1):20-6. PubMed ID: 20383215
    [Abstract] [Full Text] [Related]

  • 19. A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
    Salinger DH, Blough DK, Vicini P, Anasetti C, O'Donnell PV, Sandmaier BM, McCune JS.
    Clin Cancer Res; 2009 Aug 15; 15(16):5280-7. PubMed ID: 19671874
    [Abstract] [Full Text] [Related]

  • 20. Cellular and clinical pharmacology of fludarabine.
    Gandhi V, Plunkett W.
    Clin Pharmacokinet; 2002 Aug 15; 41(2):93-103. PubMed ID: 11888330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.